TTM
$752.14M
YoY change
-383.6%
5Y CAGR
—
Peak year (2025)
$501.58M
Cumulative operating income
−$6.03B
Operating Income history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $501.58M
Operating Income growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: -383.6%
Operating Income history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $501.58M | -383.6% | +$678.46M | ||
| 2024 | −$176.88M | -37.3% | +$105.29M | ||
| 2023 | −$282.18M | -64.1% | +$502.90M | ||
| 2022 | −$785.07M | +10.8% | −$76.42M | ||
| 2021 | −$708.65M | -14.5% | +$119.79M | ||
| 2020 | −$828.44M | -11.8% | +$110.99M | ||
| 2019 | −$939.43M | +15.3% | −$124.76M | ||
| 2018 | −$814.67M | +62.9% | −$314.58M | ||
| 2017 | −$500.09M | +17.8% | −$75.50M | ||
| 2016 | −$424.59M | +43.4% | −$128.58M | ||
| 2015 | −$296.01M | -26.9% | +$108.97M | ||
| 2014 | −$404.98M | +335.7% | −$312.04M | ||
| 2013 | −$92.94M | -28.2% | +$36.51M | ||
| 2012 | −$129.46M | +136.2% | −$74.64M | ||
| 2011 | −$54.82M | +24.4% | −$10.75M | ||
| 2010 | −$44.07M | -8.4% | +$4.04M | ||
| 2009 | −$48.11M | +72.8% | −$20.28M | ||
| 2008 | −$27.84M | -70.1% | +$65.34M | ||
| 2007 | −$93.18M | +135.9% | −$53.68M | ||
| 2006 | −$39.50M | -9.1% | +$3.97M | ||
| 2005 | −$43.47M | +34.7% | −$11.21M | ||
| 2004 | −$32.26M | +28.8% | −$7.21M | ||
| 2003 | −$25.06M | +493.5% | −$20.84M | ||
| 2002 | −$4.22M | — | — |
- 2025$501.58M-383.6%
- 2024−$176.88M-37.3%
- 2023−$282.18M-64.1%
- 2022−$785.07M+10.8%
- 2021−$708.65M-14.5%
- 2020−$828.44M-11.8%
- 2019−$939.43M+15.3%
- 2018−$814.67M+62.9%
- 2017−$500.09M+17.8%
- 2016−$424.59M+43.4%
- 2015−$296.01M-26.9%
- 2014−$404.98M+335.7%
- 2013−$92.94M-28.2%
- 2012−$129.46M+136.2%
- 2011−$54.82M+24.4%
- 2010−$44.07M-8.4%
- 2009−$48.11M+72.8%
- 2008−$27.84M-70.1%
- 2007−$93.18M+135.9%
- 2006−$39.50M-9.1%
- 2005−$43.47M+34.7%
- 2004−$32.26M+28.8%
- 2003−$25.06M+493.5%
- 2002−$4.22M—
Operating Income values are taken from Alnylam Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $752.14M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Alnylam Pharmaceuticals (ALNY) most recent annual operating income stands at $501.58M (2025) – plunged 383.6% year-over-year.
The highest annual operating income of $501.58M was reported in 2025. The lowest in the available history was −$939.43M in 2019.
Alnylam Pharmaceuticals Operating Income by Year
Alnylam Pharmaceuticals Operating Income 2025: $501.58M
Alnylam Pharmaceuticals operating income in 2025 was $501.58M, plunged 383.6% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Operating Income 2024: −$176.88M
2024's operating income for Alnylam Pharmaceuticals came in at −$176.88M, plunged 37.3% below 2023.
Alnylam Pharmaceuticals Operating Income 2023: −$282.18M
Alnylam Pharmaceuticals posted operating income of −$282.18M in 2023, plunged 64.1% below 2022.
Alnylam Pharmaceuticals Operating Income 2022: −$785.07M
In 2022, Alnylam Pharmaceuticals reported operating income of −$785.07M, grew 10.8% from 2021.
Alnylam Pharmaceuticals Operating Income 2021: −$708.65M
Alnylam Pharmaceuticals operating income in 2021 was −$708.65M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Operating Income
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation